SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : DNDN - Dendreon Corp.
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tktrimbath who wrote (731)1/7/2012 7:39:21 PM
From: DewDiligence_on_SI  Read Replies (1) of 751
 
From your blog:

››
Provenge is not a solo or a trick. The technology behind Provenge may be applicable to treating lung cancer, breast cancer, ovarian cancer, bladder cancer, renal cancer, and colo-rectal cancer.
‹‹

I disagree and think Provenge was, in fact, a lucky one shot. The drug doesn’t work the way the company claims, so it’s unlikely that the success can be replicated in other indications.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News